Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Here's Why You Should Retain BXP Stock in Your Portfolio Now
BXP is likely to gain from a premium office portfolio, a diverse tenant base and strong lab asset demand despite high debt and interest expenses.
As Roche/Genentech's Obinutuzumab ( Gazyva ) Nears FDA Decision, Spherix Global Insights White Paper Reveals Keys to Successful Lupus Product Launches
EXTON, PA, Oct. 02, 2025 ( GLOBE NEWSWIRE ) -- Spherix Global Insights has released a new white paper, Navigating the Evolving SLE/Lupus Nephritis Landscape: Keys to Successful Product Launches, which explores the critical factors shaping success in one of the most complex autoimmune markets.
Trump's pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
Pfizer's deal with Trump was a relief to the pharma industry, signaling that drugmakers could strike similar deals that would make them immune to tariffs.
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
WELLESLEY HILLS, Mass., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Climb Bio, Inc. ( Nasdaq: CLYM ) , a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., ...
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide - X4 Pharmaceuticals ( NASDAQ:XFOR ) , Altimmune ( NASDAQ:ALT )
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH ...
"LEQEMBI®" ( lecanemab ) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" ) and Biogen Inc. ( Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen" ) announced today that humanized ...
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
What's Going On With Biogen Stock - Biogen ( NASDAQ:BIIB )
On Tuesday, the U.S. Food and Drug Administration ( FDA ) issued a Complete Response Letter ( CRL ) for Biogen Inc.'s ( NASDAQ: BIIB ) supplemental New Drug Application ( sNDA ) for the high-dose regimen of nusinersen for the treatment of spinal muscular atrophy ( SMA ) .
This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Webull ( NASDAQ:BULL ) , Biogen ( NASDAQ:BIIB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Becton Dickinson ( NYSE:BDX ) , Biogen ( NASDAQ:BIIB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
National Ataxia Foundation Partners with Biogen to Bring Bill Nye "the Science Guy" Back To the Lab With New Series About Friedreich Ataxia
MINNEAPOLIS, Sept. 25, 2025 /PRNewswire/ -- The National Ataxia Foundation ( NAF ) today announced the launch of The Science Guy: Back in the Lab for FA, a new educational campaign to raise awareness and understanding of Friedreich ataxia ( FA ) , a rare, genetic disease.
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL
FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.
LEQEMBI® ( Lecanemab ) Approved for the Treatment of Alzheimer's Disease in Australia - Biogen ( NASDAQ:BIIB )
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" ) and Biogen Inc. BIIB Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.
LEQEMBI® ( Lecanemab ) Approved for the Treatment of Alzheimer's Disease in Australia
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" ) and Biogen Inc. ( Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen" ) announced today that the Therapeutic ...
Leqembi® approved for the treatment of early Alzheimer's disease in Australia - BioArctic ( OTC:BRCTF )
STOCKHOLM, Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's ( publ ) ( Nasdaq Stockholm: BIOA B ) announced today that the Therapeutic Goods Administration ( TGA ) of Australia has approved lecanemab ( Leqembi ) for the treatment of adult patients with mild cognitive impairment or mild dementia due ...
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Biogen ( NASDAQ:BIIB )
CAMBRIDGE, Mass., Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. BIIB today announced that the U.S. Food and Drug Administration ( FDA ) issued a Complete Response Letter ( CRL ) for the Company's supplemental New Drug Application ( sNDA ) for the high dose regimen of nusinersen for the ...
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
CAMBRIDGE, Mass., Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) today announced that the U.S. Food and Drug Administration ( FDA ) issued a Complete Response Letter ( CRL ) for the Company's supplemental New Drug Application ( sNDA ) for the high dose regimen of nusinersen for ...
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
Biogen's $85 Million Deal Could Change How Patients Get Spinraza Treatment - Biogen ( NASDAQ:BIIB )
Biogen acquires Alcyone for $85 million, securing full rights to ThecaFlex DRx with nusinersen. Biogen aims to launch Spinraza delivery via ThecaFlex in 2028, pending trial success. See the trading strategy with a perfect track record in 2025 [currently 35-0] → Biogen Inc.
A Look Into Biogen Inc's Price Over Earnings - Biogen ( NASDAQ:BIIB )
Looking into the current session, Biogen Inc. BIIB shares are trading at $145.60, after a 0.50% spike. Moreover, over the past month, the stock increased by 4.28%, but in the past year, fell by 27.23%.
Biogen Gets EU Nod for First Postpartum Depression Drug
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
CAMBRIDGE, Mass., Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics. As part of an existing partnership with Alcyone Therapeutics, the companies are advancing ...
Biogen Receives European Commission Approval for ZURZUVAE® ( zuranolone ) , the First and Only Treatment Approved for Women with Postpartum Depression in Europe - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Biogen ( NASDAQ:BIIB )
Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11
Biogen Receives European Commission Approval for ZURZUVAE® ( zuranolone ) , the First and Only Treatment Approved for Women with Postpartum Depression in Europe
CAMBRIDGE, Mass., Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced that the European Commission ( EC ) has granted marketing authorization for ZURZUVAE® ( zuranolone ) to treat post-partum depression ( PPD ) in adults following childbirth.
BXP Stock Gains 15.4% in Six Months: Will the Trend Last?
BXP stock is up 15.4% in six months, powered by premier office assets, tenant strength and strategic portfolio moves.
Why C4 Therapeutics Stock Crushed the Market on Monday
A major recommendation change lit a big fire under the biotech as the trading week kicked off.
Virtualware signs largest contract to date to deploy VIROO across Spain's leading vocational training centres
Bilbao, September 12, 2025 - Virtualware ( EPA:ALVIR ) , a pioneer in 3D-driven enterprise software, has signed an agreement valued at more than €5 million to roll out its VIROO platform in 66 Centres of Excellence for Vocational Training under the Ministry of Education, Vocational Training and ...
Why Is Denali Therapeutics ( DNLI ) Up 16.2% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors ...
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
China's Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug
Jiangsu Hengrui Pharmaceuticals, a Chinese developer of novel drugs, could receive up to US$1.01 billion in milestone payments after granting a US company exclusive rights to develop a heart disease drug, the latest example of mainland drug makers licensing early-stage assets to international ...
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development ...
Algernon Pharmaceuticals Announces Name Change to Algernon Health
VANCOUVER, British Columbia, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Algernon Pharmaceuticals Inc. ( the "Company" or "Algernon" ) ( CSE: AGN ) ( FRANKFURT: AGW0 ) ( OTCQB: AGNPF ) , a Canadian healthcare company announces that it is changing its name to Algernon Health.
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ ( lecanemab-irmb ) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease LEQEMBI IQLIK, if approved for initiation dosing, would be the first and ...
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
FDA Approves LEQEMBI® IQLIK™ ( lecanemab-irmb ) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months ...
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy - Biogen ( NASDAQ:BIIB )
The FDA mandates MRI screening before the third Leqembi infusion to detect ARIA-E early. ARIA-E can cause brain swelling and has been linked to seizures and deaths. Join Benzinga Real-Time Trading Chat Room for 60% Off This Labor Day The U.S.
Controlled Release Drug Delivery Market Size FDA Approved Drugs Clinical Trials Companies Report 2030
Delhi, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales and Clinical Trials Insight 2030 Report Finding and Highlights: Global Market Current Size Insight In US$ Billion: 2022 - 2030 Global Market Opportunity: > US$ 90 Billion
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study - Eli Lilly ( NYSE:LLY ) , Biogen ( NASDAQ:BIIB )
PRX012 showed 27.47 CL amyloid reduction at 400 mg, nearing FDA-defined thresholds. ARIA-E rates reached up to 41.7%, higher than those seen with Leqembi or Lilly drugs. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day
Muscular Dystrophy Association Launches #MDAstrong Campaign in September During Historic 75th Anniversary, Kicking Off on Labor Day Weekend
New York, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- This September, the Muscular Dystrophy Association ( MDA ) is launching its milestone #MDAstrong campaign during a historic moment for the organization: its 75th anniversary.
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - Stoke Therapeutics ( NASDAQ:STOK ) , Biogen ( NASDAQ:BIIB )
- 3-year data from open-label extension ( OLE ) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines -
Austria and Germany to become the first markets in the European Union ( EU ) to launch LEQEMBI® ( lecanemab ) - Biogen ( NASDAQ:BIIB )
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" ) and Biogen Inc. BIIB Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.
Austria and Germany to become the first markets in the European Union ( EU ) to launch LEQEMBI® ( lecanemab )
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" ) and Biogen Inc. ( Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen" ) announced today that the anti-amyloid ...
Austria and Germany to become the first markets in the European Union ( EU ) to launch LEQEMBI® ( lecanemab )
Austria and Germany to become the first markets in the European Union (EU) to launch ...
